Reported severe hypersensitivity reactions after i.v. iron administration in the European Economic Area (EEA) before and after implementation of risk minimisation measures

Authors:
Lennart Nathell¹, Annegret Gohlke², Stefan Wohlfeil³
1 Nathell Medical AB, Växthusvägen 6, 582 76 Linköping, Sweden,
2 IQVIA, Landshuter Allee 10, 80637 Munich, Germany
3 Winterthur, Switzerland

Corresponding author:
Annegret Gohlke
Dr.Annegret.Gohlke@iqvia.com
PH: +49 89 4579126423
Table S 1 Characteristics of i.v. iron compounds

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbohydrate shell – (non-dextran, dextran, dextran-derived) [6, 7]</td>
<td>non-dextran</td>
<td>non-dextran</td>
<td>non-dextran</td>
<td>dextran</td>
<td>dextran derived</td>
</tr>
<tr>
<td>Approved indication</td>
<td>iron deficiency</td>
<td>iron deficiency</td>
<td>iron deficiency</td>
<td>iron deficiency</td>
<td>iron deficiency</td>
</tr>
<tr>
<td>Average price in Euro in the biggest EEA countries where product is available [8]</td>
<td>12.5</td>
<td>20.0</td>
<td>no official price available</td>
<td>9.8</td>
<td>18.6</td>
</tr>
</tbody>
</table>

References